Novavax, Inc. Logo

Novavax, Inc.

NVV1.F

(2.5)
Stock Price

6,76 EUR

-15.32% ROA

38.56% ROE

-7.47x PER

Market Cap.

2.093.101.375,04 EUR

-54.03% DER

0% Yield

-33.09% NPM

Novavax, Inc. Stock Analysis

Novavax, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Novavax, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (82.35%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

With a remarkably low PBV ratio (-0.68x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a low debt to equity ratio (-26%), which means it has a small amount of debt compared to the ownership it holds

4 Revenue Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

5 Net Profit Growth

The net profit of this company has shown steady growth over the past three years, highlighting its positive financial trajectory and making it an appealing choice for potential investors.

6 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

7 ROA

The stock's ROA (-37.69%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-17), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Novavax, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Novavax, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Novavax, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Novavax, Inc. Revenue
Year Revenue Growth
1996 100.000
1997 500.000 80%
1998 700.000 28.57%
1999 1.200.000 41.67%
2000 2.475.000 51.52%
2001 24.066.000 89.72%
2002 15.005.000 -60.39%
2003 11.785.000 -27.32%
2004 8.260.000 -42.68%
2005 7.388.000 -11.8%
2006 4.683.000 -57.76%
2007 1.513.000 -209.52%
2008 1.064.000 -42.2%
2009 325.000 -227.38%
2010 343.000 5.25%
2011 14.688.000 97.66%
2012 22.076.000 33.47%
2013 20.915.000 -5.55%
2014 30.659.000 31.78%
2015 36.250.000 15.42%
2016 15.353.000 -136.11%
2017 31.176.000 50.75%
2018 34.288.000 9.08%
2019 18.662.000 -83.73%
2020 475.598.000 96.08%
2021 1.146.290.000 58.51%
2022 1.598.951.000 28.31%
2023 88.256.000 -1711.72%
2023 556.382.000 84.14%
2024 1.661.936.000 66.52%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Novavax, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1996 3.700.000
1997 2.900.000 -27.59%
1998 3.400.000 14.71%
1999 3.400.000 0%
2000 9.358.000 63.67%
2001 10.775.000 13.15%
2002 11.501.000 6.31%
2003 10.058.000 -14.35%
2004 7.369.000 -36.49%
2005 5.075.000 -45.2%
2006 11.529.000 55.98%
2007 17.600.000 34.49%
2008 24.334.000 27.67%
2009 25.780.000 5.61%
2010 28.032.000 8.03%
2011 17.885.000 -56.73%
2012 26.061.000 31.37%
2013 50.308.000 48.2%
2014 79.435.000 36.67%
2015 162.644.000 51.16%
2016 237.939.000 31.64%
2017 168.435.000 -41.26%
2018 173.797.000 3.09%
2019 113.842.000 -52.67%
2020 747.027.000 84.76%
2021 2.534.508.000 70.53%
2022 1.235.278.000 -105.18%
2023 424.916.000 -190.71%
2023 737.502.000 42.38%
2024 427.784.000 -72.4%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Novavax, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 11.090.000 100%
2009 11.928.000 7.03%
2010 10.805.000 -10.39%
2011 0 0%
2012 10.988.000 100%
2013 14.819.000 25.85%
2014 19.928.000 25.64%
2015 30.842.000 35.39%
2016 46.527.000 33.71%
2017 34.451.000 -35.05%
2018 34.409.000 -0.12%
2019 34.417.000 0.02%
2020 145.290.000 76.31%
2021 298.358.000 51.3%
2022 488.691.000 38.95%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Novavax, Inc. EBITDA
Year EBITDA Growth
1996 -5.300.000
1997 -4.700.000 -12.77%
1998 -5.200.000 9.62%
1999 -4.200.000 -23.81%
2000 -12.148.000 65.43%
2001 -5.766.000 -110.68%
2002 -20.420.000 71.76%
2003 -14.868.000 -37.34%
2004 -32.643.000 54.45%
2005 -16.661.000 -95.92%
2006 -21.892.000 23.89%
2007 -30.271.000 27.68%
2008 -32.229.000 6.08%
2009 -36.893.000 12.64%
2010 -35.262.000 -4.63%
2011 -19.830.000 -77.82%
2012 -27.789.000 28.64%
2013 -49.474.000 43.83%
2014 -84.306.000 41.32%
2015 -157.236.000 46.38%
2016 -269.113.000 41.57%
2017 -171.710.000 -56.73%
2018 -173.918.000 1.27%
2019 -138.613.000 -25.47%
2020 -416.719.000 66.74%
2021 -1.686.576.000 75.29%
2022 -633.767.000 -166.12%
2023 -469.172.000 -35.08%
2023 -487.390.000 3.74%
2024 719.444.000 167.75%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Novavax, Inc. Gross Profit
Year Gross Profit Growth
1996 400.000
1997 800.000 50%
1998 1.000.000 20%
1999 1.600.000 37.5%
2000 3.069.000 47.87%
2001 20.014.000 84.67%
2002 11.446.000 -74.86%
2003 9.728.000 -17.66%
2004 4.770.000 -103.94%
2005 1.597.000 -198.69%
2006 -1.790.000 189.22%
2007 1.292.000 238.54%
2008 1.064.000 -21.43%
2009 325.000 -227.38%
2010 343.000 5.25%
2011 7.685.000 95.54%
2012 7.384.000 -4.08%
2013 12.693.000 41.83%
2014 15.672.000 19.01%
2015 -126.394.000 112.4%
2016 -222.586.000 43.22%
2017 31.176.000 813.97%
2018 34.288.000 9.08%
2019 18.662.000 -83.73%
2020 475.598.000 96.08%
2021 1.146.290.000 58.51%
2022 696.312.000 -64.62%
2023 -307.460.000 326.47%
2023 212.614.000 244.61%
2024 1.476.968.000 85.6%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Novavax, Inc. Net Profit
Year Net Profit Growth
1996 -5.500.000
1997 -4.500.000 -22.22%
1998 -4.800.000 6.25%
1999 -4.500.000 -6.67%
2000 -12.191.000 63.09%
2001 -9.745.000 -25.1%
2002 -22.697.000 57.06%
2003 -17.273.000 -31.4%
2004 -19.069.344 9.42%
2005 -9.473.104 -101.3%
2006 -17.493.640 45.85%
2007 -23.778.251 26.43%
2008 -25.933.614 8.31%
2009 -26.746.140 3.04%
2010 -26.616.957 -0.49%
2011 -14.916.612 -78.44%
2012 -21.622.416 31.01%
2013 -37.724.894 42.68%
2014 -68.548.396 44.97%
2015 -144.469.296 52.55%
2016 -265.433.524 45.57%
2017 -153.038.780 -73.44%
2018 -161.613.116 5.31%
2019 -118.212.971 -36.71%
2020 -341.840.571 65.42%
2021 -1.534.127.780 77.72%
2022 -614.752.627 -149.55%
2023 -523.104.000 -17.52%
2023 -493.831.880 -5.93%
2024 649.524.000 176.03%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Novavax, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 -11
1997 -8 -42.86%
1998 -8 0%
1999 -6 -16.67%
2000 -13 50%
2001 -9 -50%
2002 -19 55.56%
2003 -12 -63.64%
2004 -10 -10%
2005 -4 -150%
2006 -6 20%
2007 -8 28.57%
2008 -8 0%
2009 -6 -16.67%
2010 -5 -20%
2011 -3 -150%
2012 -3 33.33%
2013 -4 25%
2014 -6 33.33%
2015 -11 45.45%
2016 -20 42.11%
2017 -10 -90%
2018 -9 -25%
2019 -5 -100%
2020 -6 20%
2021 -21 75%
2022 -8 -185.71%
2023 -5 -40%
2023 -5 -25%
2024 4 200%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Novavax, Inc. Free Cashflow
Year Free Cashflow Growth
1996 -3.400.000
1997 -4.200.000 19.05%
1998 -3.800.000 -10.53%
1999 -4.300.000 11.63%
2000 -10.875.000 60.46%
2001 -6.901.000 -57.59%
2002 -30.727.000 77.54%
2003 -19.565.000 -57.05%
2004 -31.707.000 38.29%
2005 -6.039.000 -425.04%
2006 -16.326.000 63.01%
2007 -28.703.000 43.12%
2008 -29.999.000 4.32%
2009 -33.575.000 10.65%
2010 -34.408.000 2.42%
2011 -24.239.000 -41.95%
2012 -22.570.000 -7.39%
2013 -51.144.000 55.87%
2014 -74.282.000 31.15%
2015 -144.376.000 48.55%
2016 -273.680.000 47.25%
2017 -142.885.000 -91.54%
2018 -186.197.000 23.26%
2019 -138.480.000 -34.46%
2020 -97.163.000 -42.52%
2021 265.460.000 136.6%
2022 -508.922.000 152.16%
2023 -772.773.000 34.14%
2023 -58.046.000 -1231.31%
2024 311.144.000 118.66%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Novavax, Inc. Operating Cashflow
Year Operating Cashflow Growth
1996 -3.300.000
1997 -4.200.000 21.43%
1998 -3.600.000 -16.67%
1999 -3.700.000 2.7%
2000 -10.044.000 63.16%
2001 -4.566.000 -119.97%
2002 -21.066.000 78.33%
2003 -17.547.000 -20.05%
2004 -30.099.000 41.7%
2005 -5.809.000 -418.14%
2006 -14.810.000 60.78%
2007 -26.742.000 44.62%
2008 -24.310.000 -10%
2009 -32.830.000 25.95%
2010 -32.852.000 0.07%
2011 -23.629.000 -39.03%
2012 -18.229.000 -29.62%
2013 -45.359.000 59.81%
2014 -67.014.000 32.31%
2015 -126.090.000 46.85%
2016 -255.467.000 50.64%
2017 -138.696.000 -84.19%
2018 -184.825.000 24.96%
2019 -136.623.000 -35.28%
2020 -42.541.000 -221.16%
2021 322.946.000 113.17%
2022 -415.937.000 177.64%
2023 -713.967.000 41.74%
2023 -39.655.000 -1700.45%
2024 314.269.000 112.62%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Novavax, Inc. Capital Expenditure
Year Capital Expenditure Growth
1996 100.000
1997 0 0%
1998 200.000 100%
1999 600.000 66.67%
2000 831.000 27.8%
2001 2.335.000 64.41%
2002 9.661.000 75.83%
2003 2.018.000 -378.74%
2004 1.608.000 -25.5%
2005 230.000 -599.13%
2006 1.516.000 84.83%
2007 1.961.000 22.69%
2008 5.689.000 65.53%
2009 745.000 -663.62%
2010 1.556.000 52.12%
2011 610.000 -155.08%
2012 4.341.000 85.95%
2013 5.785.000 24.96%
2014 7.268.000 20.4%
2015 18.286.000 60.25%
2016 18.213.000 -0.4%
2017 4.189.000 -334.78%
2018 1.372.000 -205.32%
2019 1.857.000 26.12%
2020 54.622.000 96.6%
2021 57.486.000 4.98%
2022 92.985.000 38.18%
2023 58.806.000 -58.12%
2023 18.391.000 -219.75%
2024 3.125.000 -488.51%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Novavax, Inc. Equity
Year Equity Growth
1996 5.100.000
1997 6.500.000 21.54%
1998 3.000.000 -116.67%
1999 2.800.000 -7.14%
2000 31.824.000 91.2%
2001 27.493.000 -15.75%
2002 8.073.000 -240.55%
2003 35.944.000 77.54%
2004 33.281.000 -8%
2005 49.652.000 32.97%
2006 94.001.000 47.18%
2007 63.065.000 -49.05%
2008 45.489.000 -38.64%
2009 74.465.000 38.91%
2010 59.050.000 -26.1%
2011 53.849.000 -9.66%
2012 80.240.000 32.89%
2013 203.234.000 60.52%
2014 229.618.000 11.49%
2015 292.669.000 21.54%
2016 -5.546.000 5377.12%
2017 -101.732.000 94.55%
2018 -167.935.000 39.42%
2019 -186.017.000 9.72%
2020 627.209.000 129.66%
2021 -351.673.000 278.35%
2022 -634.078.000 44.54%
2023 -678.350.000 6.53%
2023 -716.927.000 5.38%
2024 -431.706.000 -66.07%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Novavax, Inc. Assets
Year Assets Growth
1996 5.700.000
1997 6.800.000 16.18%
1998 3.800.000 -78.95%
1999 4.500.000 15.56%
2000 56.529.000 92.04%
2001 67.115.000 15.77%
2002 57.505.000 -16.71%
2003 84.159.000 31.67%
2004 77.993.000 -7.91%
2005 84.382.000 7.57%
2006 121.877.000 30.76%
2007 91.291.000 -33.5%
2008 76.625.000 -19.14%
2009 85.605.000 10.49%
2010 74.844.000 -14.38%
2011 66.576.000 -12.42%
2012 102.345.000 34.95%
2013 235.937.000 56.62%
2014 276.002.000 14.52%
2015 386.038.000 28.5%
2016 394.301.000 2.1%
2017 302.493.000 -30.35%
2018 207.978.000 -45.44%
2019 172.957.000 -20.25%
2020 1.582.479.000 89.07%
2021 2.576.753.000 38.59%
2022 2.258.679.000 -14.08%
2023 1.657.157.000 -36.3%
2023 1.797.490.000 7.81%
2024 1.818.646.000 1.16%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Novavax, Inc. Liabilities
Year Liabilities Growth
1996 600.000
1997 300.000 -100%
1998 800.000 62.5%
1999 1.700.000 52.94%
2000 24.705.000 93.12%
2001 39.622.000 37.65%
2002 49.432.000 19.85%
2003 48.215.000 -2.52%
2004 44.712.000 -7.83%
2005 34.730.000 -28.74%
2006 27.876.000 -24.59%
2007 28.226.000 1.24%
2008 31.136.000 9.35%
2009 11.140.000 -179.5%
2010 15.794.000 29.47%
2011 12.727.000 -24.1%
2012 22.105.000 42.42%
2013 32.703.000 32.41%
2014 46.384.000 29.5%
2015 93.369.000 50.32%
2016 399.847.000 76.65%
2017 404.225.000 1.08%
2018 375.913.000 -7.53%
2019 358.974.000 -4.72%
2020 955.270.000 62.42%
2021 2.928.426.000 67.38%
2022 2.892.757.000 -1.23%
2023 2.335.507.000 -23.86%
2023 2.514.417.000 7.12%
2024 2.250.352.000 -11.73%

Novavax, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
5.29
Net Income per Share
-1.75
Price to Earning Ratio
-7.47x
Price To Sales Ratio
2.67x
POCF Ratio
135.87
PFCF Ratio
-88.82
Price to Book Ratio
-4.49
EV to Sales
2.1
EV Over EBITDA
-7.21
EV to Operating CashFlow
115.3
EV to FreeCashFlow
-69.85
Earnings Yield
-0.13
FreeCashFlow Yield
-0.01
Market Cap
2,09 Bil.
Enterprise Value
1,65 Bil.
Graham Number
10.7
Graham NetNet
-7.9

Income Statement Metrics

Net Income per Share
-1.75
Income Quality
-0.05
ROE
0.39
Return On Assets
-0.14
Return On Capital Employed
-0.44
Net Income per EBT
0.98
EBT Per Ebit
0.91
Ebit per Revenue
-0.37
Effective Tax Rate
-0.02

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.6
Stock Based Compensation to Revenue
0.08
Gross Profit Margin
0.54
Operating Profit Margin
-0.37
Pretax Profit Margin
-0.34
Net Profit Margin
-0.33

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.1
Free CashFlow per Share
-0.16
Capex to Operating CashFlow
2.65
Capex to Revenue
0.05
Capex to Depreciation
0.83
Return on Invested Capital
1.5
Return on Tangible Assets
-0.15
Days Sales Outstanding
14.93
Days Payables Outstanding
81.22
Days of Inventory on Hand
9.32
Receivables Turnover
24.44
Payables Turnover
4.49
Inventory Turnover
39.18
Capex per Share
0.26

Balance Sheet

Cash per Share
7,07
Book Value per Share
-2,91
Tangible Book Value per Share
-3.74
Shareholders Equity per Share
-2.91
Interest Debt per Share
1.67
Debt to Equity
-0.54
Debt to Assets
0.13
Net Debt to EBITDA
1.96
Current Ratio
1.04
Tangible Asset Value
-0,56 Bil.
Net Current Asset Value
-1,05 Bil.
Invested Capital
627002000
Working Capital
0,05 Bil.
Intangibles to Total Assets
0.07
Average Receivables
0,03 Bil.
Average Payables
0,07 Bil.
Average Inventory
12475000
Debt to Market Cap
0.11

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Novavax, Inc. Dividends
Year Dividends Growth

Novavax, Inc. Profile

About Novavax, Inc.

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

CEO
Mr. John Charles Jacobs M.B.A.
Employee
1.543
Address
21 Firstfield Road
Gaithersburg, 20878

Novavax, Inc. Executives & BODs

Novavax, Inc. Executives & BODs
# Name Age
1 Mr. John Joseph Trizzino B.S., M.B.A.
President & Chief Operating Officer
70
2 Mr. Troy Morgan Esq., J.D.
Senior Vice President, Deputy General Counsel & Chief Compliance Officer
70
3 Mr. John Charles Jacobs M.B.A.
President, Chief Executive Officer & Director
70
4 Mr. James Patrick Kelly C.F.A.
Executive Vice President, Chief Financial Officer & Treasurer
70
5 Mr. Mark Casey
Executive Vice President, Chief Legal Officer & Corporate Secretary
70
6 Dr. Robert Walker M.D.
Senior Vice President, Chief Medical Officer and Interim Head of R&D
70
7 Ms. Erika S. Trahan
Associate Director of Investor & Public Relations
70
8 Mr. Ian J. Watkins
Executive Vice President & Chief Human Resources Officer
70
9 Ms. Silvia Taylor M.B.A.
Executive Vice President and Chief Corporate Affairs & Advocacy Officer
70
10 Mr. Richard P. Crowley
Executive Vice President & Chief Operating Officer
70

Novavax, Inc. Competitors

Moderna, Inc. Logo
Moderna, Inc.

0QF.F

(1.2)
BioNTech SE Logo
BioNTech SE

22UA.F

(2.2)
CureVac N.V. Logo
CureVac N.V.

5CV.F

(1.0)